K1C20_BOVIN KRT20 ELISA tesk kit
- Known as:
- K1C20_BOVIN KRT20 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen15977
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- K1C20_BOVIN KRT20 ELISA tesk kit
Related genes to: K1C20_BOVIN KRT20 ELISA tesk kit
- Gene:
- KRT20 NIH gene
- Name:
- keratin 20
- Previous symbol:
- -
- Synonyms:
- CK20, K20, MGC35423
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-02-04
- Date modifiied:
- 2016-03-09
Related products to: K1C20_BOVIN KRT20 ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: K1C20_BOVIN KRT20 ELISA tesk kit
- Pediatric ureteropelvic junction obstruction (UPJO) is the leading cause of congenital obstructive uropathy. Experimental models have identified local urothelial remodeling in UPJO and implicated this remodeling as a protective adaptation to preserve kidney structural integrity and function. We investigated the expression of urothelial proteins in human urine and resected tissue specimens from children with UPJO in a pilot study. - Source: PubMed
Publication date: 2026/07/10
Jackson Ashley RGupta SudiptiKercsmar MacieFroehlich John WLee Richard SBecknell BrianChing Christina B - Hirschsprung disease (HSCR) is characterized by distal aganglionosis. Persistent postoperative dysmotility and enterocolitis suggest that intrinsic epithelial vulnerabilities may remain within the ganglionic bowel. We here aimed to define both the state of the epithelium and its metabolism in HSCR. - Source: PubMed
Publication date: 2026/07/07
Zhao YitongYang JielinLi BoLee DorothyXiong YiPierro AgostinoJiang Qian - BackgroundThis study assessed the potential utility of GATA3, cyclin D1, KRT20, and GLUT1 immunohistochemistry (IHC) markers for diagnosing renal epithelial tumors.MethodsA retrospective analysis was conducted on all eligible specimens ( = 95) diagnosed at our institution between 2014 and 2024. IHC was done and the staining intensity and distribution of selected IHC markers were assessed.ResultsAmong 95 specimens, 26% were clear cell renal cell carcinoma, 21% were chromophobe RCC, and 17% were papillary RCC. Less frequent subtypes included TFE3-rearranged RCC, clear cell papillary renal cell tumor (CCPRT), papillary renal neoplasm with reverse polarity (PRNRP), and eosinophilic solid and cystic RCC (ESC-RCC). Clear cell RCC and CCPRT were consistently positive for cyclin D1 and GLUT1, and negative for GATA3/KRT20. CCPRT showed strong, diffuse GLUT1, unlike the limited staining in papillary RCC. PRNRP was positive for GATA3, cyclin D1, and GLUT1, and negative for KRT20. While chromophobe RCC exhibited variable GATA3 and GLUT1 expression with weak to moderate cyclin D1 positivity, oncocytomas were strong cyclin D1 positive, with negative GATA3, KRT20, and GLUT1. All 3 ESC-RCC specimens were KRT20 positive.ConclusionsOur findings validate many previously reported observations and characterize adjunctive patterns of these less commonly used markers across renal tumor subtypes. It suggests GATA3 as a potential diagnostic tool for PRNRP, while GLUT1 demonstrates differential expression patterns for papillary RCC and CCPRT, aiding in distinguishing papillary renal tumors. Similarly, cyclin D1 appears to be a valuable adjunct in differentiating oncocytoma from chromophobe RCC. Also, KRT20 shows high specificity for ESC-RCC. - Source: PubMed
Publication date: 2026/06/25
Barakzai Muhammad AbrarArain Shoukat AliAfsar Nasir AliAlsouss Yara ObaedaAl-Hussain Turki - Cytokeratin 20 (CK20) expression in colorectal cancer (CRC) exhibits significant intratumoral heterogeneity, posing challenges for tissue microarray (TMA)-based immunohistochemical assessment. Optimal TMA design parameters (core diameter and number) remain undefined. This study aimed to determine optimal TMA parameters for CK20 detection using an optimized virtual TMA (vTMA) simulation strategy. A total of 154 CRC cases were included. Whole slide images of CK20-stained sections were used as reference standards. An optimized vTMA approach involving unrestricted candidate core generation, non-overlapping sampling constraints, and 1000 repeated simulations per parameter combination was employed. Consistency between vTMA-derived CK20 positivity and whole-slide reference was evaluated using intraclass correlation coefficients (ICC) across core diameters (0.6 mm and 1.0 mm) and numbers (1-4). A single 0.6 mm core achieved moderate consistency (ICC = 0.711, 95% CI: 0.710-0.713; RMSE = 0.188). Increasing the core diameter to 1.0 mm substantially improved consistency to a good level (ICC = 0.796, 95% CI: 0.795-0.797; RMSE = 0.150). Using three 1.0 mm cores provided excellent consistency (ICC = 0.922; RMSE = 0.086), with incremental improvements beyond three cores being minimal. Compared with conventional fixed-core pool approaches, the optimized vTMA strategy reduced confidence interval widths by up to 11.5-fold in single-core simulations and by approximately 4.3-fold in four-core simulations. A single 1.0 mm core achieves good agreement with whole-section CK20 assessment, while three 1.0 mm cores optimize consistency beyond 0.90, minimizing sampling error. The optimized vTMA strategy offers a robust framework for TMA parameter optimization in heterogeneous biomarker studies. - Source: PubMed
Publication date: 2026/05/28
Li ShunLi YanyuZhao YaoHuang ChuwenLv LaiHuang Yan - Breast cancer (BC) subtypes such as HR+, HER2+, and triple-negative (TNBC) show distinct molecular features, treatment responses, and outcomes. DNA methylation is a key, targetable epigenetic regulator in BC. This study examined whether the DNA methyltransferase inhibitor decitabine (DAC) produces subtype-specific epigenomic and transcriptional effects in breast cancer cell lines representing distinct molecular subtypes. - Source: PubMed
Publication date: 2026/05/26
Shafqat AreezArora ItikaAkbar ArshiyaAlfuwais MohammedAldubaisi SafiahKhan Mohammad ImranAbu-Zaid AhmedAhmed FirozYaqinuddin Ahmed